Fintel reports that on January 10, 2025, Stifel downgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from Buy to Hold ...

周五，Stifel分析师调整了对Repare Therapeutics（纳斯达克股票代码：RPTX）股票的展望，将目标价从之前的4.00美元下调至3.00美元，同时仍维持对该股的买入评级。目前，该公司股价为1.31美元，市值约为5600万美元。

周五，Stifel分析师维持Align Technology股票的买入评级，目标价保持在275.00美元。这一积极立场源于该公司正在进行的重组计划，分析师认为这将为实现2025年每股收益 (EPS)超过10美元的预期目标提供更多时间。Align Technology以其Invisalign正畸设备而闻名，同时还持有每股14美元的大量现金。

We recently compiled a list of the 13 AI News and Ratings on Wall Street’s Radar. In this article, we are going to take a ...

The highly anticipated Assassin's Creed Shadows, initially slated for release in November, has now been postponed for the ...

An index of St. Louis-area publicly traded stocks underperformed the broad stock market averages in 2024. The equally ...

Stifel analysts raised their price target to $31.00 from $26.00 and reiterated a Buy rating on Rocket Lab ( RKLB, Financial) ...

In a report released today, Cole McGill from Stifel Nicolaus maintained a Buy rating on Lithium Americas Corp. (LAC – Research Report), with a ...

PRIEST RIVER — Senior Palmer Coleman and junior Ian Lamanna hit one free throw each with less than two seconds to go as the ...

The stock fell 6.2% to $140.14 in New York, marking the biggest single-day decline in four months. Though the Nvidias latest ...

The company had slowed its M&A spending to focus on reducing debt, but CEO Patrick Dovigi said during an investor call that ...

As reported by Reuters, Wall Street’s main indexes rose on Monday to more than one-week highs, driven by a rally in ...